Trial · NCT03625323
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of Objective Response Rate (ORR) According to iRECIST (Unconfirmed) | Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 68 months | ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Primary | Evaluation of Objective Response Rate (ORR) According to iRECIST (Confirmed) | Data collected from screening until time of disease progression, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 68 months | ORR was defined as the percentage of participants for each dose level whose best overall response is rated as iCR or iPR per immune Response Evaluation Criteria In Solid Tumors (iRECIST) for target lesions and assessed by CT or MRI. iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Secondary | Duration of (Serious) Adverse Events | up to 27 months | |
| Secondary | Frequency of (Serious) Adverse Events | up to 27 months | |
| Secondary | Severity of (Serious) Adverse Events | up to 27 months | |
| Secondary | Time to Responses According to iRECIST and RECIST 1.1 | up to 68 months | |
| Secondary | Duration of Responses According to iRECIST and RECIST 1.1 | up to 68 months | |
| Secondary | Response Rate According to RECIST 1.1 | up to 68 months | |
| Secondary | Disease Control Rate According to iRECIST and RECIST 1.1 | up to 68 months | |
| Secondary | Progression Free Survival (PFS) | up to 68 months | |
| Secondary | Overall Survival (OS) | up to 68 months | |
| Secondary | Occurrence of Eftilagimod Alpha-specific Antibodies (ADA) | up to 24 month | |
| Secondary | Plasma Concentration Time Profile of Eftilagimod Alpha | up to 24 month |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03625323/registered